^
Association details:
| Biomarker: | EWSR1-FLI1 fusion |
|---|---|
| Cancer: | Ewing Sarcoma |
| Drug: | Yondelis (trabectedin) (Alkylating agent, DNA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).
Published date:
05/25/2023
Excerpt:
This multicenter dose escalation study employed a standard 3+3 design. T was given as a 1-h infusion on day (D)1 with low dose I intravenously on D2 and 4 of a 21D cycle. Dose limiting toxicities (DLTs) were evaluated in cycle one. Eligibility required confirmed EWS::FLI1 fusion transcript...At DL 2 and above, there were 4 PRs, 6 SD in 14 evaluable pts (Table).
Secondary therapy:
irinotecan
DOI:
10.1200/JCO.2023.41.16_suppl.11519
Trial ID:
